October 24, 2016 / 10:22 AM / 10 months ago

BRIEF-Fennec reports update of Siopel 6 study on Sodium Thiosulfate

Oct 24 (Reuters) - Fennec Pharmaceuticals Inc :

* Fennec announces update of Siopel 6 study on Sodium Thiosulfate (STS) presented at the International Society Of Paediatric Oncology (SIOP) 2016 meeting

* Fennec pharmaceuticals inc - final audiometry results will be available at end of 2017

* Fennec - combination of CIS+STS was generally well tolerated

* Fennec - no difference in event free survival and overall survival at 2 years for cisplatin alone versus Cisplatin + Sts with no evidence of tumor protection Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below